One M&T Plaza, Suite 2000 Buffalo, New York 14203-2391

Telephone: 716.856.4000 Facsimile: 716.849.0349



A Registered Limited Liability Partnership Including Professional Associations

Please deliver the following pages to:

Name:

U.S. Patent and Trademark Office

Phone Number: Company:

Company: Fascimile:

1.703.872.9306

From: Date: Rachel Watt

Monday, February 09, 2004 3:41:52 PM

09

Total Pages: Comments: RECEIVED
CENTRAL FAX CENTER

FEB 1 1 2004

OFFICIAL

## Confidentiality Notice

This is a CONFIDENTIAL transmission. The sender, Hodgson Russ LLP, is a law firm representing its client. The transmission is intended for the designated addressee only. If you are not the intended recipient, please contact us immediately and REFRAIN FROM DISCLOSING OR USING THE ENCLOSED INFORMATION IN ANY WAY. Failure to comply with this direction may result in a claim that you have violated the law and/or are liable for money damages. Thank you for your attention to this message.

(If you have received this transmission in error, please notify us by telephone 716.848.1558 immediately so the we can arrange for the return of the documents to us at no cost to you.)

In the event of missing pages or other problems with the transmission of this Facsimile, please call: 716.848.1558

Albany • Boca Raton • Buffalo • Johnstown • JFK International Airport

New York City • Newark • Palm Beach Gardens • Toronto • www.hodgsonruss.com

FEB 1 1 2004

Attorney Docket No.: 11520

FACSIMILE TRANSMISSION CERTIFICATE

I hereby certify that this paper is being transmitted to the U.S. Patent and Trademark Office to (703) 872-9306 on the date shown below.

Rachel Watt

<u>February 9, 2004</u>

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

Applicant

Jui H. WANG, et al.

Serial No.

10/728,491

Filing Date

December 5, 2003

Title HIGH EFFICACY ANTISENSE RI.

PKA POLY-DNP

**OLIGORIBONUCLEOTIDES** 

**PRELIMINARY AMENDMENT** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Prior to examination, please amend the above-identified patent application as follows:

Amendments to the Specification begin on page 2 of this paper.

The Listing of Claims begins on page 3 of this paper (no amendments are currently made).

Remarks begin on page 8 of this paper.